Clinical and demographic characteristics of 27 HBV+ patients treated with TNF-α-blocking agents (TNFBA).
| Study | Disease | Age, Sex | TNFBA | DMARD | HBV Status | LAM Prophylaxis | HBV Reactivation (HBV–DNA)* | LAM Therapy | Outcome Followup (mo) |
|---|---|---|---|---|---|---|---|---|---|
| 13 | CD | 40 M | INF | — | Cirrhosis | NA | NA | Y | Stable (36) |
| 23 | RA | 73 M | ETA | — | Chronic hepatitis | NA | NA | Y | Discontinued LAM for resistance (36) |
| 2 | CD | 26 M | INF | AZA | IC | Y | N | NA | Well (4) |
| 11 | RA | 58 M | INF, ETA | — | IC | Y | N | NA | Well (24) |
| 12 | AS | 32 M | INF | — | IC | Y | Y (< 10,000) | NA | Well (12) |
| 16 | RA | 54 M | ETA, ADA | MTX | IC | Y | N | NA | Well (21) |
| 16 | AS | 49 M | INFL | — | IC | Y | N | NA | Well (7) |
| Present #1 | RA | 73 F | ETA | IC | Y | N | NA | Well (36), discontinued LAM 12 mo after ETA | |
| Present #2 | RA | 67 F | INF | MTX | IC | Y | N | NA | Well (43) |
| 15 | RA | 36 F | INF | — | IC | N | N | NA | Well (12) |
| 19 | AS | 41 M | INF, ETA | IC | N | N | NA | Well, with raised ALT (54) | |
| 22 | RA | 55 F | ETA | MTX | IC | N | N | NA | Well (13) |
| 22 | AS | 38 F | ETA | — | IC | N | N | NA | Well (12) |
| 4 | AOSD | 28 F | INF | — | IC | N | N | Y | Liver transplant |
| 3 | CD | 50 M | INF | AZA | IC | N | Y (> 10,000) | Y | Well (2) |
| 10 | RA | 49 F | INF | MTX | IC | N | Y (> 10,000) | Y | Well (2) |
| 14 | AS | 35 F | INF | MTX | IC | N | Y (> 10,000) | Y | Well, continue INF (4) |
| 20 | CD | 43 F | INF | IC | N | Y (> 10,000) | Y | Well (13) | |
| 19 | AS | 43 F | INF | — | IC | N | Y (not specified) | Y | Well (56) |
| 16 | RA | 53 M | ETA | — | IC | N | Y (< 10,000) | Y | Well (6) |
| 21 | RA | 62 F | ETA | MTX, HCQ | IC | N | Y (< 10,000) | Y | Well, restarted ETA (6) |
| Present #3 | RA | 56 F | ADA | SSZ | IC | N | Y (< 10,000) | Y | Well (12), discontinued LAM 12 mo after ADA |
| 2 | CD | 34 M | INF | AZA | IC | N | Y (> 10,000) | N | Spontaneous resolution |
| 2 | CD | 38 M | INF | AZA | IC | N | Y (> 10,000) | N | Fulminant hepatitis, death |
| 17 | CD | 29 F | INF | — | IC | N | Y (> 10,000) | N | Well, persistent viral replication (8) |
| 18 | CD | 41 F | INF | — | OC | N | Y (> 10,000) | Y | Well, discontinued LAM after 10 mo |
| 24 | AS | 73 M | ETA | — | OC | N | Y (< 10,000) | Y | Well, restarted ETA (4) |
↵* Data are copies/ml. Y: yes, N: no. HBV: hepatitis B virus; CD: Crohn’s disease; RA: rheumatoid arthritis; AS: ankylosing spondylitis; AOSD: adult onset Still’s disease; INF: infliximab; ETA: etanercept; ADA: adalimumab; DMARD: disease modifying antirheumatic drug; AZA: azathioprine; MTX: methotrexate; HCQ: hydroxychloroquine; SSZ: sulfasalazine; IC: inactive carrier; OC: occult carrier; LAM: lamivudine; NA: not applicable; ALT: alanine aminotransferase.